Marcaine 0,5 % Adrénaline (Epinephrine, Bupivacaine Hydrochloride, Anhydrous)

Bupivacaine blocks voltage‑gated sodium channels on nerve membranes, preventing depolarisation and halting nerve impulse transmission. Epinephrine causes local vasoconstriction, which slows systemic absorption of bupivacaine and extends its anesthetic effect.

The dose is determined by the prescribing clinician based on the type of procedure, patient weight, and clinical guidelines. Only a qualified healthcare professional should calculate and administer the appropriate amount.

Safety in pregnancy and lactation has not been definitively established. The product should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Marcaine combines bupivacaine, which has a longer duration of action than lidocaine, with epinephrine to further prolong effect and reduce systemic absorption. This makes it suitable for procedures requiring extended anesthesia, whereas shorter‑acting agents may be preferred for brief interventions.

Marcaine 0,5 % Adrénaline should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability.

The solution is administered by a qualified healthcare professional via injection, either epidurally or by infiltration into the target tissue. Proper aseptic technique and aspiration before injection are essential to avoid intravascular administration.

Serious risks include cardiac arrhythmias, seizures, methemoglobinemia, and severe allergic reactions such as anaphylaxis. Immediate medical attention is required if any of these events occur.

Patients with known hypersensitivity to bupivacaine, epinephrine, or any component of the formulation should avoid this product. Caution is also advised in individuals with severe cardiac disease, uncontrolled hypertension, or significant hepatic impairment.